BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment

BeiGene’s (BGNE) BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms received FDA orphan designation in treatment of Waldenstrom macroglobulinemia, according to a post on the agency’s site.